Johnson Chemical Pharmaceutical Works Co Ltd (4747) - Total Assets
Based on the latest financial reports, Johnson Chemical Pharmaceutical Works Co Ltd (4747) holds total assets worth NT$1.99 Billion TWD (≈ $62.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4747 total equity for net asset value and shareholders' equity analysis.
Johnson Chemical Pharmaceutical Works Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Johnson Chemical Pharmaceutical Works Co Ltd's total assets have evolved over time, based on quarterly financial data.
Johnson Chemical Pharmaceutical Works Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Johnson Chemical Pharmaceutical Works Co Ltd's total assets of NT$1.99 Billion consist of 68.0% current assets and 32.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 54.5% |
| Accounts Receivable | NT$101.05 Million | 5.1% |
| Inventory | NT$140.90 Million | 7.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Johnson Chemical Pharmaceutical Works Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Johnson Chemical Pharmaceutical Works Co market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Johnson Chemical Pharmaceutical Works Co Ltd's current assets represent 68.0% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 54.5% of total assets in 2024, up from 21.3% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 7.2% of total assets.
Johnson Chemical Pharmaceutical Works Co Ltd Competitors by Total Assets
Key competitors of Johnson Chemical Pharmaceutical Works Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Johnson Chemical Pharmaceutical Works Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.76 | 7.65 | 2.27 |
| Quick Ratio | 4.15 | 6.84 | 1.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.05 Billion | NT$1.14 Billion | NT$304.68 Million |
Johnson Chemical Pharmaceutical Works Co Ltd - Advanced Valuation Insights
This section examines the relationship between Johnson Chemical Pharmaceutical Works Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.49 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | NT$1.97 Billion |
| Market Capitalization | $77.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Johnson Chemical Pharmaceutical Works Co Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Johnson Chemical Pharmaceutical Works Co Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Johnson Chemical Pharmaceutical Works Co Ltd (2009–2024)
The table below shows the annual total assets of Johnson Chemical Pharmaceutical Works Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.97 Billion ≈ $61.92 Million |
-1.39% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.79 Million |
+91.77% |
| 2022-12-31 | NT$1.04 Billion ≈ $32.74 Million |
+1.18% |
| 2021-12-31 | NT$1.03 Billion ≈ $32.36 Million |
-6.50% |
| 2020-12-31 | NT$1.10 Billion ≈ $34.61 Million |
+15.42% |
| 2019-12-31 | NT$951.76 Million ≈ $29.99 Million |
+1.59% |
| 2018-12-31 | NT$936.82 Million ≈ $29.51 Million |
+0.62% |
| 2017-12-31 | NT$931.07 Million ≈ $29.33 Million |
-2.56% |
| 2016-12-31 | NT$955.50 Million ≈ $30.10 Million |
+4.13% |
| 2015-12-31 | NT$917.57 Million ≈ $28.91 Million |
+22.02% |
| 2014-12-31 | NT$752.00 Million ≈ $23.69 Million |
+10.01% |
| 2013-12-31 | NT$683.60 Million ≈ $21.54 Million |
+50.49% |
| 2012-12-31 | NT$454.24 Million ≈ $14.31 Million |
+2.84% |
| 2011-12-31 | NT$441.70 Million ≈ $13.92 Million |
+11.40% |
| 2010-12-31 | NT$396.51 Million ≈ $12.49 Million |
+7.55% |
| 2009-12-31 | NT$368.69 Million ≈ $11.62 Million |
-- |
About Johnson Chemical Pharmaceutical Works Co Ltd
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, card… Read more